Impaired plasmalogens in patients with schizophrenia

Rima Kaddurah-Daouk, Joseph Patrick McEvoy, Rebecca Baillie, Hongjie Zhu, Jeffrey K. Yao, Vishwajit L. Nimgaonkar, Peter F Buckley, Matcheri S. Keshavan, Anastasia Georgiades, Henry A. Nasrallah

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.

Original languageEnglish (US)
Pages (from-to)347-352
Number of pages6
JournalPsychiatry Research
Volume198
Issue number3
DOIs
StatePublished - Aug 15 2012

Fingerprint

Plasmalogens
Schizophrenia
Healthy Volunteers
Glycerophospholipids
Recurrence
Membranes
Neurobiology
Nervous System Diseases
Phosphatidylcholines
Antipsychotic Agents
Lipoproteins
Phospholipids
Biomarkers
Serum
Pharmaceutical Preparations

Keywords

  • Drug-naïve
  • Lipidomics
  • Metabolomics
  • Phospholipids
  • Plasmalogen
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kaddurah-Daouk, R., McEvoy, J. P., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., ... Nasrallah, H. A. (2012). Impaired plasmalogens in patients with schizophrenia. Psychiatry Research, 198(3), 347-352. https://doi.org/10.1016/j.psychres.2012.02.019

Impaired plasmalogens in patients with schizophrenia. / Kaddurah-Daouk, Rima; McEvoy, Joseph Patrick; Baillie, Rebecca; Zhu, Hongjie; K. Yao, Jeffrey; Nimgaonkar, Vishwajit L.; Buckley, Peter F; Keshavan, Matcheri S.; Georgiades, Anastasia; Nasrallah, Henry A.

In: Psychiatry Research, Vol. 198, No. 3, 15.08.2012, p. 347-352.

Research output: Contribution to journalArticle

Kaddurah-Daouk, R, McEvoy, JP, Baillie, R, Zhu, H, K. Yao, J, Nimgaonkar, VL, Buckley, PF, Keshavan, MS, Georgiades, A & Nasrallah, HA 2012, 'Impaired plasmalogens in patients with schizophrenia', Psychiatry Research, vol. 198, no. 3, pp. 347-352. https://doi.org/10.1016/j.psychres.2012.02.019
Kaddurah-Daouk R, McEvoy JP, Baillie R, Zhu H, K. Yao J, Nimgaonkar VL et al. Impaired plasmalogens in patients with schizophrenia. Psychiatry Research. 2012 Aug 15;198(3):347-352. https://doi.org/10.1016/j.psychres.2012.02.019
Kaddurah-Daouk, Rima ; McEvoy, Joseph Patrick ; Baillie, Rebecca ; Zhu, Hongjie ; K. Yao, Jeffrey ; Nimgaonkar, Vishwajit L. ; Buckley, Peter F ; Keshavan, Matcheri S. ; Georgiades, Anastasia ; Nasrallah, Henry A. / Impaired plasmalogens in patients with schizophrenia. In: Psychiatry Research. 2012 ; Vol. 198, No. 3. pp. 347-352.
@article{ad69f74cb6104c628804f4f6c1a6b60a,
title = "Impaired plasmalogens in patients with schizophrenia",
abstract = "Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-na{\"i}ve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.",
keywords = "Drug-na{\"i}ve, Lipidomics, Metabolomics, Phospholipids, Plasmalogen, Schizophrenia",
author = "Rima Kaddurah-Daouk and McEvoy, {Joseph Patrick} and Rebecca Baillie and Hongjie Zhu and {K. Yao}, Jeffrey and Nimgaonkar, {Vishwajit L.} and Buckley, {Peter F} and Keshavan, {Matcheri S.} and Anastasia Georgiades and Nasrallah, {Henry A.}",
year = "2012",
month = "8",
day = "15",
doi = "10.1016/j.psychres.2012.02.019",
language = "English (US)",
volume = "198",
pages = "347--352",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Impaired plasmalogens in patients with schizophrenia

AU - Kaddurah-Daouk, Rima

AU - McEvoy, Joseph Patrick

AU - Baillie, Rebecca

AU - Zhu, Hongjie

AU - K. Yao, Jeffrey

AU - Nimgaonkar, Vishwajit L.

AU - Buckley, Peter F

AU - Keshavan, Matcheri S.

AU - Georgiades, Anastasia

AU - Nasrallah, Henry A.

PY - 2012/8/15

Y1 - 2012/8/15

N2 - Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.

AB - Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.

KW - Drug-naïve

KW - Lipidomics

KW - Metabolomics

KW - Phospholipids

KW - Plasmalogen

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84868642991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868642991&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2012.02.019

DO - 10.1016/j.psychres.2012.02.019

M3 - Article

C2 - 22513041

AN - SCOPUS:84868642991

VL - 198

SP - 347

EP - 352

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -